Person: OKUYAN, BETÜL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
OKUYAN
First Name
BETÜL
Name
16 results
Search Results
Now showing 1 - 10 of 16
Publication Metadata only Preparing future pharmacists to provide effective behaviour change support in pharmaceutical care consultations: early adoption of the Train4Health educational products(2022-06-01) OKUYAN, BETÜL; OKUYAN B., Henriques H. R., Felix I. B., Braam K., Pimenta N., Guerreiro M. P., Carmo M. B.Publication Metadata only Assessment of medication literacy in breastfeeding women: preliminary data(2022-12-01) SANCAR, MESUT; OKUYAN, BETÜL; Ucar N., SANCAR M., Sezerol M. A., Buyukkayh D., Tasci Y., OKUYAN B.Publication Metadata only Medication adherence barriers in Turkish patients with chronic diseases(2022-12-01) SANCAR, MESUT; AY, NADİYE PINAR; OKUYAN, BETÜL; Yagmur M., SANCAR M., Ay P., Abdi A., Samuelyan N., OKUYAN B.Publication Open Access Medication reconciliation service in hospitalized patients with infectious diseases during coronavirus disease-2019 pandemic: An observational study(2023-08-01) ENVER, CÜNEYD; ERTÜRK ŞENGEL, BUKET; SANCAR, MESUT; KORTEN, VOLKAN; OKUYAN, BETÜL; ENVER C., ERTÜRK ŞENGEL B., SANCAR M., KORTEN V., OKUYAN B.Objectives: To determine the prevalence and type of medication discrepancies and factors associated with unintentional discrepancies and identify the rate of hospital readmission and emergency service visit within 30 days after discharge among hospitalized patients with infectious diseases and receiving clinical pharmacist-led medication reconciliation during the coronavirus disease-2019 (COVID-19) pandemic. Materials and Methods: This observational study was conducted in the internal medicine and infectious diseases wards of a tertiary university hospital between July 2020 and February 2021 among hospitalized adult patients with infectious diseases. Medication reconciliation service (including patient counseling) was provided in person or by telephone. The number and type of medication discrepancies detected during the medication reconciliation services, the acceptance rate of pharmacists’ recommendation, and factors associated with having at least one unintentional medication discrepancy at admission were evaluated. At follow-up, hospital readmission and emergency service visit within 30 days after discharge were assessed by telephone. Results: Among 146 patients, 84 (57.5%) had at least one unintentional discrepancy at admission. Only three unintentional discrepancies were determined in three patients at hospital discharge. All the pharmacists’ recommendations for medication discrepancies were accepted by the physicians. Having COVID-19 [odds ratio (OR): 2.25, 95% confidence interval (CI): 1.15-4.40; p<0.05], being at a high risk for medication error (OR: 2.01, 95% CI: 1.03-3.92; p<0.05), and higher number of medications used at home (OR: 1.41, 95% CI: 1.23-1.61; p<0.001) were associated with having at least one unintentional discrepancy at admission. The rates of 30 day hospital readmission and admission to the emergency medical service were 12.3% and 15.8%, respectively. Conclusion: Medication reconciliation service provided by in-person or by telephone was useful for detecting and solving unintentional medication discrepancies during the COVID-19 pandemic.Publication Open Access The effect of Cotinus coggygria L. ethanol extract in the treatment of burn wounds(2022-01-01) OKUYAN, BETÜL; ŞEN, ALİ; ŞENER, GÖKSEL; ERCAN, FERİHA; Erta B., OKUYAN B., ŞEN A., ERCAN F., Onel H., GÖGER F., Sener G.The overall aim of the present research is to evaluate for the first time the curative effect of Cotinus coggygria leaves on burn injury in an experimental burn model along with its anti-inflammatory and antioxidant activity potential. Also, phenolic compounds of C. coggygria were characterised by LC-MS/MS. Wistar albino rats weighing 200-250 g were exposed to 90 degrees C bath for 10 s to induce burn injury, involving 30% of the total body surface area. In the treatment groups, 5% C. coggygria ethanol extract was applied topically as a cream immediately after the burn. Blood and skin tissue samples were taken after decapitation at the 4th and 48th hours following the burn procedure. Interleukin 1-beta (IL-1 beta) and tumour necrosis factor (TNF-alpha) were determined in serum samples, and hydroxyproline, prostoglandin E2 (PGE2), and myeloperoxidase (MPO) activity and 8-hydroxy-2\"-deoxy-guanosine (8-OHdG) levels were determined in skin tissue samples. Increased levels of serum cytokines were decreased with C. coggygria treatment in both periods. MPO activity, prostaglandine (PGE2), and 8-OhdG levels increased, while hydroxyproline levels decreased due to burn damage. On the other hand, these parameters were returned to its normal levels with C. coggygria treatment. In addition, the tissue histology of animals treated with C. coggygria showed a complete epithelialization with increased collagenation. As a result, C. coggygria may be an alternative treatment approach for burns-induced skin damage and wounds.Publication Metadata only Development of a theory planned behavior based scale to assess turkish clinical pharmacists' intention to provide pharmaceutical care(2022-12-01) SANCAR, MESUT; OKUYAN, BETÜL; ÖZDEMİR N., Tecen-Yucel K., KARA E., Demirkan K., SANCAR M., OKUYAN B.Publication Open Access The impact of clinical pharmacist-led hypertension screening at the community pharmacy in Türkiye(2022-01-01) OKUYAN, BETÜL; SANCAR, MESUT; Demircioglu Akyilmaz C. E. , OKUYAN B., SANCAR M.© 2022 Marmara University Press.The aim of this study was to evaluate the impact of clinical pharmacist-led hypertension screening program (including referring high-risk individuals who are not aware of being hypertensive or prehypertensive to the physician) at a community pharmacy in Türkiye. This prospective observational pilot study was conducted in a community pharmacy located in Mersin-Türkiye between October 2017 and April 2018. Blood pressure measurements were performed by the clinical pharmacist at baseline and follow-up. The rate of participants who had high blood pressure measurements (≥140 mmHg for systolic and/or ≥90 mmHg for diastolic) was determined at the baseline by clinical pharmacist. According to the guidelines, participants with high blood pressure were referred directly to the physician by the clinical pharmacist. In the follow-up, the number of patients diagnosed with prehypertension or hypertension and the changes in their measurement of blood pressure were identified between baseline and follow-up. According to findings of clinical pharmacist-led blood pressure measurement, 23 (37.1%) out of 62 participants with high blood pressure were referred to the physician by the clinical pharmacist. In the follow-up, it was determined that 12 patients (52.2%) out of 23 participants were diagnosed with hypertension by a physician and eight patients (34.8%) out of 23 participants had prehypertensive. According to the findings of this pilot study, it was determined a positive impact of the clinical pharmacist-led hypertension screening program for high-risk individuals for hypertension.Publication Open Access Scope, content and quality of clinical pharmacy practice guidelines: a systematic review(2023-01-01) OKUYAN, BETÜL; Paudyal V., OKUYAN B., Henman M. C., Stewart D., Fialová D., Hazen A., Lutters M., Oleárová A., Weidmann A. E., Wirth F., et al.Background: Guidelines for pharmacy practitioners regarding various clinical pharmacy activities have been published in a number of countries. There is a need to review the guidelines and identify the scope of activities covered as a prelude to developing internationally acceptable common guidelines. Aim: To review the scope of clinical pharmacy guidelines and assess the extent to which these guidelines conform to quality standards as per the AGREE II instrument. Method: Medline, Embase, Guideline Central, International Pharmaceutical Abstracts, Google Scholar and Google (for grey literature) were searched for the period 2010 to January 2023. Guidelines which focused on any health care setting and any clinical pharmacy activity were included. Data were extracted and quality assessed independently by two reviewers using the English version of the AGREE II instrument. Results: Thirty-eight guidelines were included, mostly originating from Australia (n = 10), Ireland (n = 8), UK (n = 7) and USA (n = 5). Areas covered included medication reconciliation, medicines optimisation, medication management and transition of care. As per the AGREE II assessment, the highest score was obtained for the scope and purpose domain and the lowest score for rigour of development, mainly due to non-consideration of literature/evidence to inform guideline development. Conclusion: Clinical pharmacy guidelines development processes need to focus on all quality domains and should take a systematic approach to guideline development. Guidelines need to further emphasise person-centred care and clinical communication. There is a scope to harmonise the guidelines internationally considering the diverse practices, standards and legislations across different geographies.Publication Metadata only Factors associated with intention of breastfeeding and pregnant women to have the Coronavirus vaccine(2022-12-01) OKUYAN, BETÜL; Ucar N., Bayrak O., Buyukkayh D., Cetin A., OKUYAN B.Publication Metadata only Therapeutic drug monitoring in pediatric patients treated with anti-tuberculosis medications by high performance liquid chromatography(2022-01-01) OKUYAN, BETÜL; TOK, FATİH; KARAKUŞ, SEVGİ; KAYMAKÇIOĞLU, BEDİA; SANCAR, MESUT; OKUYAN B., TOK F., KARAKUŞ S., Dalgiç N., ÇAKIR E., Midyat L., Koçyiğit-Kaymakçioğlu B., Berk U. E. , İZZETTİN F. V. , Rollas S., et al.© 2022 Marmara University Press.The aim of this study is to perform therapeutic drug monitoring for isoniazid (INH), rifampicin (RIF), and pyrazinamide (PZA) in pediatric tuberculosis patients. The study was carried out in 3 different training-research hospitals in Istanbul, Türkiye between 2011 and 2012. The pediatric patients (aged ≤14 years) who initiated the standard primary anti-tuberculosis therapy were included in this study. The serum samples were collected 3 hours after the first medication doses were given on the 5th day of treatment. Chromatographic experiments were performed on an Agilent 1100 High-Performance Liquid Chromatography (HPLC) system, and the separation was carried out on a Nova-Pak C18 (3.9x150 mm, 5 μm, Merck) analytical column. In this HPLC method, the gradient elusion delivered 3% to 40% (v/v) acetonitrile in phosphate buffer was used, and diode array detector. Twenty-three children (60.9% male) patients were included with a mean age of 111.70 ± 59.94 months. Plasma levels were measured sub-therapeutically for INH in 14, RIF in 10, and PZA in 5 patients, according to the normal range of adult patients. Maximum plasma concentrations after three hours were found between 0.53-14.02 mg/L for INH, 11.17-60.39 mg/L for PZA, 2.15-16.75 mg/L for RIF. In conclusion, this method has been successfully applied to simultaneously determine RIF, INH, and PZA plasma levels in pediatric tuberculosis patients. RIF and INH plasma levels were found to be lower in pediatric patients with tuberculosis compared to target range of adult patients.